The latest announcement is out from Standard BioTools (LAB).
Standard BioTools Inc. is streamlining its workforce by 10% and reshuffling senior management after merging with SomaLogic, Inc. to enhance operational efficiency and cut costs as part of a long-term strategy. Expected restructuring expenses are projected to be between $10 million to $11 million, with payments spread over the next three quarters. However, final costs could vary due to unforeseen factors associated with the restructuring.
See more data about LAB stock on TipRanks’ Stock Analysis page.
